Clinical, epidemiological and therapeutic characteristics of Mycoplasma genitalium infection in a French STI center - 26/01/22
, Romain Palich a, e, Nagisa Godefroy a, Anne Simon b, Jérôme Robert c, Cécile Bébéar d, Wladimir Sougakoff c, Rachid Agher a, Eric Caumes a, e, Gentiane Monsel a, bBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 5 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Mycoplasma genitalium (MG) infection was highly prevalent in PrEP (HIV pre-exposure prophylaxis) users and HIV-positive patients with a rate of 17% and 25%, respectively. |
• | Nearly 90% of the MG positive patients were asymptomatic, while nearly 20% were coinfected with Chlamydia trachomatis or Neisseria gonorrhoeae. |
• | MG treatment was challenging for patients with high risk of reinfection, with therapeutic failure rates above 50% after first-line and second-line treatments. |
Abstract |
Objectives |
We report the characteristics of Mycoplasma genitalium (MG) infection in patients from a STI center in Paris. We evaluated outcomes after treatment.
Methods |
We included all patients tested for MG, Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infection in our center from January 2017 to December 2018, using multiplex PCR on urine specimen, vaginal or rectal swabs. We collected data regarding sex, age, HIV status, PrEP use, sexual behavior, NG and CT co-infection, symptoms and treatment.
Results |
MG infection prevalence was 7% (397/5586) (95% CI 6.4–7.8). It ranged from 4.6% in patients consulting for routine STI testing (3.9% in women, 5% in men), to 16% in HIV-positive patients and 25% in PrEP users. Among the 397 MG infected patients, 351 (88%) were asymptomatic and 87 (22%) were co-infected with NG or CT. Among the 270 (68%) treated patients, 249 (92%) received azithromycin. Failure rate was 74% in the 103 patients tested post-treatment. Treatment failure tended to be higher with azithromycin single dose than with 5-day azithromycin (88% vs. 70%; P=0.07). Azithromycin and moxifloxacin were used as second-line treatment in 24 and 23 patients, respectively. Post-treatment PCR remained positive in 55% of the 44 tested patients with a better eradication rate with moxifloxacin than with azithromycin (70% vs. 33%; P=0.04).
Conclusion |
MG infection is highly prevalent in PrEP users and HIV-positive patients and is mostly asymptomatic. Management of MG infection should be tailored and adapted to the risk of antibiotic resistance and reinfection.
Le texte complet de cet article est disponible en PDF.Keywords : Management, Mycoplasma genitalium, PrEP, STI
Plan
| ☆ | Part of this work was presented at the Journées dermatologiques de Paris in December 2020. |
Vol 52 - N° 1
P. 13-17 - février 2022 Retour au numéro
Article précédent
- Prevention and control of highly antibiotic-resistant bacteria in a Pacific territory: Feedback from New Caledonia between 2004 and 2020
- Julien Colot, Claire Fouquet, Frédérique Ducrocq, Sylvie Chevalier, Christine Le Provost, Cécile Cazorla, Camille Cheval, Caroline Fijalkowski, Ann-Claire Gourinat, Antoine Biron, Cyrille Goarant, Alexandre Bourles, Benoît Marot, Philippe Saliou
- E-learning versus face-to-face training: Comparison of two learning methods for Lyme borreliosis
- M. Gaudin, G. Tanguy, M. Plagne, A. Saussac, Y. Hansmann, B. Jaulhac, M. Kelly, L. Ouchchane, O. Lesens, expert group for the teaching of Lyme disease
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?